An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG to assess prognosis and immunotherapy response in bladder cancer patients
Open Access
- 10 September 2025
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Abstract
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival. This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82303623)
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0532300)
- Shanghai Public Health Clinical Center (Intramural funding KY-GW-2025-01)
- Open Project of Key Laboratory of Vascular Aging (HUST), Ministry of Education (VAME-2024-1)
- National Key Research and Development Program of China (2019YFA0905600)
- China Postdoctoral Science Foundation (2023M731199)
- Hubei Provincial Department of Human Resources and Social Security (Postdoctoral Innovation Research Post 331048)
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0525700)
This publication has 27 references indexed in Scilit:
- The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cellsCancer Cell, 2023
- Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)World Journal of Urology, 2023
- Cisplatin and Albumin-Based Gold–Cisplatin Nanoparticles Enhance Ablative Radiation Therapy–Induced Antitumor Immunity in Local and Distant Tumor MicroenvironmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyThe Lancet Oncology, 2021
- Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapyActa Pharmaceutica Sinica B, 2021
- STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cellsDARU Journal of Pharmaceutical Sciences, 2020
- Cancer-associated fibroblasts in tumor microenvironment – Accomplices in tumor malignancyCellular Immunology, 2019
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Immunogenic cell death in cancer and infectious diseaseNature Reviews Immunology, 2016
- Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapyEuropean Journal of Immunology, 2014